The MAVERICK trial found that MRI surveillance alone significantly improved cognitive failure-free survival by 40% compared to MRI plus PCI in patients with limited-stage and extensive-stage small-cell lung cancer. Serious treatment-related adverse events were also less frequent with MRI surveillance alone.
Researchers developed a wearable electroceutical platform with microneedle electrodes that deliver stable electrical stimulation while reducing the influence of sweat or dead skin cells. The device can be remotely controlled via smartphone and automatically detaches when skin overheats for enhanced safety.
The phase III TAISHAN-302 trial found Tam-Peli to significantly improve overall survival, progression-free survival, and objective response rate in patients with relapsed small-cell lung cancer compared to topotecan. The study also showed a favorable safety profile for Tam-Peli.
The EVOKE-03/KEYNOTE-D46 trial found a numerically longer progression-free survival and higher response rates with sacituzumab govitecan plus pembrolizumab, but no statistically significant benefit in PFS or OS for patients with PD-L1-high metastatic NSCLC
The Phase III ARTEMIS-008 trial shows that risvutatug rezetecan significantly improves overall survival in patients with relapsed small-cell lung cancer. The treatment reduced the risk of death by 54% and improved progression-free survival and response rates compared to topotecan.
A phase 3 trial shows ivonescimab significantly improves overall survival compared to pembrolizumab in patients with PD-L1-positive advanced NSCLC. The median overall survival was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab.
A simple perception test using standard eye testing equipment can accurately predict the success of laser surgery for age-related vision loss. The test identified 1.66% of patients who were not suitable for the treatment, while 96.9% successfully adapted to their laser blended vision.
The phase 1b DeLLphi-308 study found that subcutaneous tarlatamab achieved serum exposures comparable to the approved intravenous dosing while maintaining a favorable safety profile, with 30% preliminary objective response rate in patients with ES-SCLC.
A Phase 1 study showed the investigational therapy demonstrated a manageable safety profile, with 33.3% of patients achieving objective response at the recommended 2.5mg/kg dose. The treatment was well-tolerated, with no treatment-related deaths and only one patient discontinuing due to an adverse event.
Results from the DeLLphi-309 study suggest that extended-interval dosing regimens of tarlatamab may offer patients greater treatment flexibility while maintaining comparable clinical activity. The study found improved overall survival rates with less frequent dosing schedules, but with similar treatment-emergent adverse event rates.
The investigational combination of pumitamig and elfetabart drozuntecan demonstrated encouraging early antitumor activity in patients with small cell lung cancer, with a 70.4% overall response rate. The combination also showed a manageable safety profile, supporting further clinical development.
The Phase 3 IMpower030 trial found that perioperative atezolizumab plus chemotherapy doubled event-free survival to 62.8 months compared to 34.9 months for chemotherapy alone. The study also showed higher pathological response rates with the atezolizumab regimen.
A Phase III trial found that local consolidative therapy after dual immunotherapy did not improve overall or progression-free survival in patients with metastatic NSCLC. The study tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control.
Researchers at Tokyo Metropolitan University identified how deadly E. coli bacteria spread using a chain-like adherence pattern under flow, and discovered a new gene family mediating this process. This discovery provides new insights into infection mechanisms and potential treatments for LEE-negative strains.